GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation

Cell Reports

Volumn 13, Issue 10, 2015, Pages 2064-2071

  Poirier, Steve ^a,b   Mamarbachi, Maya ^a   Chen, Wan Ting ^c   Lee, Amy S ^c   Mayer, Gaetan ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; GLUCOSE REGULATED PROTEIN 94; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE 9; CHOLESTEROL; MEMBRANE PROTEIN; PCSK9 PROTEIN, MOUSE; SERINE PROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM HOMEOSTASIS; CARBOXY TERMINAL SEQUENCE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; ENZYME REGULATION; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN INTERACTION; ANIMAL; BLOOD; GENETIC TRANSFECTION; IMMUNOPRECIPITATION; KNOCKOUT MOUSE; MASS SPECTROMETRY; METABOLISM; SIZE EXCLUSION CHROMATOGRAPHY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CHOLESTEROL; CHROMATOGRAPHY, GEL; HEPATOCYTES; IMMUNOPRECIPITATION; MALE; MASS SPECTROMETRY; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; TRANSFECTION;

EID: 85027923395     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.11.006     Document Type: Article

References (26)

1. Abifadel, M., Varret, M., Rabès, J.P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34 (2003), 154–156.
2. Benjannet, S., Rhainds, D., Hamelin, J., Nassoury, N., Seidah, N.G., The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J. Biol. Chem. 281 (2006), 30561–30572.
3. Bu, G., Geuze, H.J., Strous, G.J., Schwartz, A.L., 39 kDa receptor-associated protein is an ER resident protein and molecular chaperone for LDL receptor-related protein. EMBO J. 14 (1995), 2269–2280.
4. Chen, W.T., Tseng, C.C., Pfaffenbach, K., Kanel, G., Luo, B., Stiles, B.L., Lee, A.S., Liver-specific knockout of GRP94 in mice disrupts cell adhesion, activates liver progenitor cells, and accelerates liver tumorigenesis. Hepatology 59 (2014), 947–957.
5. Cohen, J., Pertsemlidis, A., Kotowski, I.K., Graham, R., Garcia, C.K., Hobbs, H.H., Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37 (2005), 161–165.
6. Culi, J., Mann, R.S., Boca, an endoplasmic reticulum protein required for wingless signaling and trafficking of LDL receptor family members in Drosophila. Cell 112 (2003), 343–354.
7. Cunningham, D., Danley, D.E., Geoghegan, K.F., Griffor, M.C., Hawkins, J.L., Subashi, T.A., Varghese, A.H., Ammirati, M.J., Culp, J.S., Hoth, L.R., et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14 (2007), 413–419.
8. Goldstein, J.L., Brown, M.S., Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation 76 (1987), 504–507.
9. Jansen, G., Määttänen, P., Denisov, A.Y., Scarffe, L., Schade, B., Balghi, H., Dejgaard, K., Chen, L.Y., Muller, W.J., Gehring, K., Thomas, D.Y., An interaction map of endoplasmic reticulum chaperones and foldases. Mol. Cell. Proteomics 11 (2012), 710–723.
10. Lee, A.S., Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat. Rev. Cancer 14 (2014), 263–276.
11. Mangrum, J.B., Martin, E.J., Brophy, D.F., Hawkridge, A.M., Intact stable isotope labeled plasma proteins from the SILAC-labeled HepG2 secretome. Proteomics 15 (2015), 3104–3115.
12. Marzec, M., Eletto, D., Argon, Y., GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum. Biochim. Biophys. Acta 1823 (2012), 774–787.
13. Maxwell, K.N., Breslow, J.L., Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. USA 101 (2004), 7100–7105.
14. Maxwell, K.N., Soccio, R.E., Duncan, E.M., Sehayek, E., Breslow, J.L., Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J. Lipid Res. 44 (2003), 2109–2119.
15. Mayer, G., Poirier, S., Seidah, N.G., Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J. Biol. Chem. 283 (2008), 31791–31801.
16. McNutt, M.C., Lagace, T.A., Horton, J.D., Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J. Biol. Chem. 282 (2007), 20799–20803.
17. Ni, M., Lee, A.S., ER chaperones in mammalian development and human diseases. FEBS Lett. 581 (2007), 3641–3651.
18. Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., Ginsberg, H.N., Masana, L., Descamps, O.S., Wiklund, O., Hegele, R.A., Raal, F.J., Defesche, J.C., et al., European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34 (2013), 3478–3490.
19. Poirier, S., Mayer, G., The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des. Devel. Ther. 7 (2013), 1135–1148.
20. Poirier, S., Mayer, G., Poupon, V., McPherson, P.S., Desjardins, R., Ly, K., Asselin, M.C., Day, R., Duclos, F.J., Witmer, M., et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J. Biol. Chem. 284 (2009), 28856–28864.
21. Randow, F., Seed, B., Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability. Nat. Cell Biol. 3 (2001), 891–896.
22. Seidah, N.G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S.B., Stifani, S., Basak, A., Prat, A., Chretien, M., The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA 100 (2003), 928–933.
23. Seidah, N.G., Poirier, S., Denis, M., Parker, R., Miao, B., Mapelli, C., Prat, A., Wassef, H., Davignon, J., Hajjar, K.A., Mayer, G., Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS ONE, 7, 2012, e41865.
24. Stebbins, C.E., Russo, A.A., Schneider, C., Rosen, N., Hartl, F.U., Pavletich, N.P., Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89 (1997), 239–250.
25. Supino-Rosin, L., Yoshimura, A., Yarden, Y., Elazar, Z., Neumann, D., Intracellular retention and degradation of the epidermal growth factor receptor, two distinct processes mediated by benzoquinone ansamycins. J. Biol. Chem. 275 (2000), 21850–21855.
26. Wu, S., Hong, F., Gewirth, D., Guo, B., Liu, B., Li, Z., The molecular chaperone gp96/GRP94 interacts with Toll-like receptors and integrins via its C-terminal hydrophobic domain. J. Biol. Chem. 287 (2012), 6735–6742.